Research Institute for Medicines (iMED.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal,
Serviço de Medicina Interna, Centro Hospitalar Psiquiátrico de Lisboa (CHPL), Lisboa, Portugal.
Clin Interv Aging. 2019 Mar 4;14:535-547. doi: 10.2147/CIA.S192252. eCollection 2019.
Cardiovascular diseases (CVDs) are extremely common among the elderly, but information on the use of potentially inappropriate medications (PIMs) with cardiovascular risk is scarce. We aimed to determine the prevalence of PIMs with risk of cardiac and cerebrovascular adverse events (CCVAEs), including major adverse cardiac and cerebrovascular events (MACCE).
A cross-sectional study was performed using a convenience sample from four long-term care facilities and one community pharmacy in Portugal. Patients were included if they were aged 65 or older and presented at least one type of medication in their medical and pharmacotherapeutic records from 2015 until December 2017. The main outcome was defined as the presence of PIMs with risk of MACCE and was assessed by applying a PIM-MACCE list that was developed from a previous study. All medications included in this list were assessed for their availability in Portugal.
A total of 680 patients were included. Of those, 428 (63%) were female with a mean age of 78.4±8.1 years. Four-hundred and four (59.4%) patients were taking medications associated with CCVAEs risk (mean =1.7±1.0 drugs/patient), including 264 patients (38.8%) who used drugs with MACCE risk (mean =1.4±0.8 drugs/patient). Fifty percent of patients with a previous history of CVD (n=521) were taking PIMs with risk of CCVAEs, including 30.0% with risk of MACCE.
Our findings show that 50% of patients with previous history of CVD were taking drugs with risk of CCAVEs and 30% with risk of MACCE. More tailored tools for the management of drug therapy in elderly patients with CVD are of major importance in clinical practice.
心血管疾病(CVD)在老年人中极为常见,但有关具有心血管风险的潜在不适当药物(PIM)使用的信息却很少。我们旨在确定具有心脏和脑血管不良事件(CCVAEs)风险的 PIM 的患病率,包括主要不良心脏和脑血管事件(MACCE)。
本研究采用葡萄牙四个长期护理机构和一个社区药房的便利样本进行了一项横断面研究。如果患者年龄在 65 岁或以上,并且在 2015 年至 2017 年 12 月期间的医疗和药物治疗记录中至少有一种药物,则将其纳入研究。主要结局定义为存在具有 MACCE 风险的 PIMs,并通过应用从先前研究中开发的 PIM-MACCE 清单进行评估。本清单中包含的所有药物均在葡萄牙进行了评估。
共纳入 680 例患者。其中,428 例(63%)为女性,平均年龄为 78.4±8.1 岁。404 例(59.4%)患者服用与 CCVAEs 风险相关的药物(平均=1.7±1.0 种药物/患者),其中 264 例(38.8%)患者服用具有 MACCE 风险的药物(平均=1.4±0.8 种药物/患者)。521 例(76.6%)有 CVD 既往史的患者正在服用具有 CCVAEs 风险的 PIMs,其中 30.0%有 MACCE 风险。
我们的研究结果表明,50%有 CVD 既往史的患者正在服用具有 CCVAEs 风险的药物,其中 30%有 MACCE 风险。在临床实践中,更针对 CVD 老年患者药物治疗管理的工具至关重要。